Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Watch an on-demand webcast and download slides from a live symposium covering the latest on HER3- and TROP2-targeted antibody‒drug conjugates for NSCLC, breast cancer, and other solid tumors.

Share

Program Content

Activities

ADC Overview
An Overview of ADCs: Key Structural Features and Potential Adverse Events
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 20, 2023

TROP2 ADCs
Evolution of TROP2-Targeted ADCs in Solid Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 20, 2023

HER3 ADCs
HER3 as a Target for ADCs: Rationale and Clinical Evidence
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 19, 2023

Activities

TROP2 and HER3 ADCs
Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 23, 2023

Expires: May 22, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.